Fig. 3. mTORC1 promotes oncogenic Met-dependent anchorage-independent and tumor growth.

(A) Relative colony area of wild-type, M1268T (N=6 independent biological replicates) and D1246N MET-expressing cells (N=3 independent biological replicates) grown in soft agar and treated with DMSO or wortmannin (100 nM). (B) Relative colony area of wild-type, M1268T and D1246N MET-expressing cells (N=3 independent biological replicates) and U87MG cells (N=4 independent biological replicates) grown in soft agar and treated with DMSO or rapamycin (2 nM). (C and D) Western blots for phosphorylated p70-S6K and mTOR (Ser²⁴⁸¹) in lysates from wild-type, M1268T and D1246N MET-expressing cells treated with DMSO, LY294002 (LY, 10 μM) or PHA-665752 (PHA, 100 nM). N= 3 or 4 independent biological replicates. (E and F) Tumour volume of graft of 5x10⁵ cells expressing wild-type, M1268T or D1246N MET injected subcutaneously into nude mice. Tumors were measured daily and, at 30-50 mm3, treated topically with DMSO or rapamycin (2 nM), then assessed at days 4 (E) and 6 (F) thereafter. N=5 mice per group. Data (A to F) are mean values ± SEM. Student’s t test (compared to control or as indicated): NS, non-significant; *P<0.05, **P<0.01, ***P<0.005.